Dapagliflozin (10 mg) significantly reduced ALT, AST, and GGT levels, according to a retrospective study [150], while empagliflozin (10 mg/d) also attenuated liver steatosis and liver stiffness, indicative of potential antifibrotic activity, in a small-scale RCT [151]. The gene discussed is GPT; the disease is fatty liver disease.